Avant Technologies' JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies
June 17 2025 - 8:00AM
InvestorsHub NewsWire
LAS VEGAS, NV -- June 17, 2025 --
InvestorsHub NewsWire -- Avant Technologies Inc. (OTCQB:
AVAI) (“Avant” or the “Company”), and its JV partner, Ainnova
Tech, Inc., (Ainnova), a leading healthcare technology company
focused on revolutionizing early disease detection using artificial
intelligence (AI), today announced that screenings for diabetic
retinopathy begin this week in collaboration with Grupo Dökka and
its leading pharmacy subsidiaries, Fischel Pharmacies and La Bomba
Pharmacies located in Central America.
Both Fischel and La Bomba
Pharmacies have asked their diabetic customers to schedule a free
screening as part of a collaborative program where Ainnova will use
its cutting-edge AI platform, Vision AI, to help identify changes
in the retina using a quick and non-invasive scan of the patient’s
retina.
Vinicio Vargas, Chief Executive
Officer at Ainnova and a member of the Board of Directors of
Ai-nova Acquisition Corp., a joint venture company created by both
Avant and Ainnova, said of the benefits for the collaboration, “As
we begin similar initiatives in Mexico, our goal is to close the
patient care loop with timely treatment - connecting every step of
the journey. We are integrating pharma, retail, ophthalmologists,
and our technology into a unified experience, all driven by one
incentive: the well-being of the diabetic patient. Projects like
this allow us to validate the model across diverse populations and
sectors as part of our strategy to reach the market in a smarter,
more efficient way - where the biggest winners are the
patients.”
Diabetic retinopathy is one of the
main causes of vision loss in people with diabetes. Although, in
its early stages, it may not present symptoms, it can be detected
with a simple and quick screening. The screenings are
important for:
Prevention: Screenings will detect changes in the
retina before they affect vision.
Speed: Each screening takes only a few
minutes.
Peace of
Mind: Patients will receive the results of the screening
in a secure and timely manner.
Grupo Dökka, which operates in
Costa Rica, Nicaragua, and Panama with expansion expected into
other Central American countries, has created numerous innovative
platforms, including storage and distribution, pharmacies, and
marketing and sales, that provide access to comprehensive health
and well-being solutions for all people.
About Ainnova Tech
Inc.
Ainnova is a Nevada-based
healthtech startup with headquarters in San Jose, Costa Rica, and
Houston, Texas. Founded by an experienced and innovative team that
is dedicated to leveraging artificial intelligence for early
disease detection. Recognized with multiple global awards and
renowned partnerships with hospitals and medical device companies,
we proudly introduce Vision AI - our cutting-edge platform designed
to prevent blindness and detect the early onset of diabetes.
Explore how Ainnova is revolutionizing healthcare through advanced
technology and proactive solutions.
About Avant Technologies,
Inc.
Avant Technologies Inc. is an
emerging technology company developing solutions in artificial
intelligence in healthcare. With a focus on pushing the boundaries
of what is possible in AI and machine learning, Avant serves a
diverse range of industries, driving progress and efficiency
through state-of-the-art technology.
More information about Avant can be
found at https://avanttechnologies.com
You can also follow us on social
media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking
Statements
Certain statements contained in
this press release may constitute “forward-looking
statements.” Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
because of various important factors as disclosed in our filings
with the Securities and Exchange Commission located at their
website (http://www.sec.gov). In
addition to these factors, actual future performance, outcomes, and
results may differ materially because of more general factors
including (without limitation) general industry and market
conditions and growth rates, economic conditions, governmental and
public policy changes, the Company’s ability to raise capital on
acceptable terms, if at all, the Company’s successful development
of its products and the integration into its existing products and
the commercial acceptance of the Company’s products. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect
to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do
so. These forward-looking statements should not be
relied upon as representing the Company's views as of any date
after the date of the press release.
Contact:
Avant Technologies Inc.
info@avanttechnologies.com
Avant Technologies (QB) (USOTC:AVAI)
Historical Stock Chart
From Jun 2025 to Jul 2025
Avant Technologies (QB) (USOTC:AVAI)
Historical Stock Chart
From Jul 2024 to Jul 2025